Lead Therapy Trial Fuels aTyr Pharma’s (ATYR) Promising Upside, Leerink Stays Bullish

aTyr Pharma Inc. (NASDAQ:ATYR) is one of the best multibagger stocks to invest in right now. On August 22, Leerink Partners’ Faisal Khurshid reiterated a Buy rating on aTyr Pharma Inc. (NASDAQ:ATYR) with a $16 price target. His view reflects optimism around the EFZO-FIT trial, which is testing efzofitimod as a potential treatment for pulmonary sarcoidosis. Lead Therapy Trial Fuels aTyr Pharma (ATYR) Promising Upside, Leerink Stays Bullish Tonhom1009/Shutterstock.com Khurshid highlights that feedback fro ...